Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
allogeneic NK cell infusion + rituximab + sargramostim
- Development stage
- Discontinued
- Lead developer
- University of Texas MD Anderson Cancer Center
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Monoclonal Antibodies → Antibody-Based Therapeutics, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intravenous, Subcutaneous
01
Overview
This combination therapy consists of an infusion of donor-derived (allogeneic) natural killer (NK) cells, the anti-CD20 monoclonal antibody rituximab, and the cytokine recombinant human granulocyte-macrophage colony-stimulating factor (rhu-GMCSF, sargramostim). Developed at the M.D. Anderson Cancer Center, the regimen is designed to treat patients with recurrent B-cell malignancies, such as chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL), following a non-myeloablative allogeneic stem cell transplant. The mechanism involves rituximab-mediated opsonization of malignant B-cells, which are then targeted for destruction by the infused NK cells via antibody-dependent cellular cytotoxicity (ADCC). Sargramostim is administered to enhance the activity and recruitment of the immune effector cells, potentially boosting the ADCC effect and overall anti-tumor response.
- Brand names
- RituxanLeukine
- Other names
- NK cell infusionRituximabGM-CSFrhu-GMCSFsargramostimNK Cells, Rituximab, and GM-CSF for Post-Transplant Lymphoid Malignancies
02
Targets
FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A)CD20 (B-lymphocyte antigen CD20)CSF2R (Granulocyte-macrophage colony-stimulating factor receptor)
Beyond the preview
Go deeper on allogeneic NK cell infusion + rituximab + sargramostim.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on allogeneic NK cell infusion + rituximab + sargramostim.